Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. has reported significant advancements in 2023, including the U.S. FDA’s Orphan Drug Designation for its XRx-008 program targeting ADPKD, and alignment with the FDA for a Phase 3 trial under accelerated approval guidelines. The company has also achieved progress in drug manufacturing and non-clinical studies, while preparing for a registration clinical trial aimed at marketing approval. These milestones, alongside successful funding and organizational developments, position XORTX for potential value creation in its pursuit of treatments for progressive kidney disease.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
